Richard B. Lipton, MD

June 29, 2021

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

June 15, 2021

The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.

June 10, 2021

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

June 08, 2021

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

March 25, 2021

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

March 14, 2021

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.

February 22, 2021

The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.

February 18, 2021

The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.

February 11, 2021

The director of the Montefiore Headache Center discussed how rimegepant was observed to produce clinically meaningful improvements in migraine prevention.

January 29, 2021

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.